Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$19.12
+4.0%
$18.85
$13.37
$32.27
$606.22M1.38264,856 shs101,602 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.61
+10.4%
$6.88
$1.89
$11.64
$59.67M1.34780,817 shs4.70 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.35
+7.4%
$3.57
$2.28
$6.71
$539.13M1.71.16 million shs494,558 shs
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$5.90
-1.4%
$6.28
$2.36
$7.48
$697.89M0.461.43 million shs993,025 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
0.00%+8.42%+2.93%+18.58%-27.73%
INmune Bio, Inc. stock logo
INMB
INmune Bio
0.00%-51.13%-64.56%-64.17%-67.40%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+18.53%+51.04%+12.40%+55.91%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%+4.91%-12.52%-2.55%+120.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
1.6051 of 5 stars
3.60.00.00.03.30.80.0
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.6059 of 5 stars
3.30.00.00.02.01.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.1731 of 5 stars
3.03.00.04.30.64.20.6
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.2802 of 5 stars
4.71.00.00.03.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.13
Buy$53.00177.27% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40606.33% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0037.93% Upside
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.30
Buy$20.88254.05% Upside

Current Analyst Ratings Breakdown

Latest INMB, DNTH, TRVI, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
7/1/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00
5/28/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$21.00
5/20/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
5/13/2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$6.24M98.52N/AN/A$11.91 per share1.60
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K6,142.59N/AN/A$1.45 per share1.80
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.14$0.21 per share20.37$2.09 per share2.08
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$1.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/6/2025 (Estimated)

Latest INMB, DNTH, TRVI, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/6/2025Q1 2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.13-$0.09+$0.04-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
15.98
15.99
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
15.38
15.38

Institutional Ownership

CompanyInstitutional Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%

Insider Ownership

CompanyInsider Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8.15%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8032.16 million29.54 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1023.58 million15.17 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
20117.29 million95.83 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Predicts TRVI FY2025 Earnings
Analysts Offer Predictions for TRVI FY2025 Earnings
TRVI Trevi Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$19.11 +0.74 (+4.00%)
As of 07/3/2025 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.60 +0.25 (+10.38%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.55 -0.06 (-2.11%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.35 +0.30 (+7.41%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$4.20 -0.15 (-3.33%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$5.90 -0.08 (-1.40%)
As of 07/3/2025 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.